Dr Reddys Laboratories (RDY) Total Liabilities (2009 - 2026)

Dr Reddys Laboratories (RDY) has reported Total Liabilities for 10 consecutive years, with $2.1 billion the latest figure, recorded in Q1 2026.

• Quarterly Total Liabilities rose 16.22% year-over-year to $2.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 billion (up 16.22% YoY) and the FY2026 annual result came in at $2.1 billion, up 16.22% from the prior year.
• Total Liabilities climbed to $2.1 billion in Q1 2026 per RDY's latest filing, from $1.8 billion in the prior quarter.
• Over the last five years, Total Liabilities for RDY reached as high as $2.1 billion in Q1 2026 and fell as low as $1.1 billion in Q1 2023.
• A 5-year average of $1.5 billion and a median of $1.3 billion in 2022 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2023 — Total Liabilities fell 17.95% — and 2025, when it soared 42.13%.
• Year by year, Total Liabilities stood at $1.3 billion in 2022, then declined by 17.95% to $1.1 billion in 2023, then advanced by 16.09% to $1.3 billion in 2024, then surged by 42.13% to $1.8 billion in 2025, then grew by 16.22% to $2.1 billion in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $2.1 billion, $1.8 billion, and $1.3 billion for Q1 2026, Q1 2025, and Q1 2024 respectively.